|
Malaysian Journal of Medical Sciences
School of Medical Sciences, Universiti Sains Malaysia
ISSN: 1394-195X
Vol. 10, Num. 2, 2003, pp. 27-30
|
Malaysian Journal of Medical Sciences, Vol. 10, No. 2, July 2003, pp. 27-30
REVIEW ARTICLE
MANAGEMENT OF DIABETIC NEUROPATHY
Raymond Azman Ali
Senior Consultant Neurologist, Department of Medicine,
Medical Faculty UKM
Correspondence: Prof. Dr. Raymond Azman Ali MBBS (Hons)
(Monash), M.Med (S'pore), M.Med (Mal.), MD (Monash), FRCP (Ireland), FAMM,
FRCP (Glasg.) Professor of Medicine and Senior Consultant Neurologist, Department
of Medicine, Medical Faculty, Universiti Kebangsaan Malaysia, Jalan Yaacob
Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur.
Code Number: mj03019
Diabetes mellitus is the commonest cause of neuropathy
worldwide. Diabetic neuropathy (DN) develops in about 4-10% of diabetic patients
after 5 years and in 15% after 20 years.Four main mechanisms have been postulated
to underlie the pathogenesis of DN. Diabetic neuropathy can be divided into
symmetrical and asymmetrical neuropathies. Diabetic Autonomic Neuropathy
(DAN) parallels the severity of DSN, and affects primarily the cardiovascular,
gastrointestinal, genitourinary and integumentary systems. The cornerstone
of treatment of diabetic neuropathy is optimization of glycaemic control.
Future treatments for diabetic neuropathy should address the underlying pathogenesis.
Key words : Diabetes Mellitus, Neuropathy,
Management
Diabetes mellitus is the commonest cause of neuropathy worldwide.
Diabetic neuropathy (DN) develops in about 4-10% of diabetic patients after
5 years and in 15% after 20 years. (1) Longer duration of diabetes, type I
diabetes mellitus, the male gender and co-existent hypertension are risk factors
for the development of DN. (2) The diagnosis of diabetic neuropathy must be
based on clinical symptoms, objective neurological signs, and electrodiagnostic
confirmation. (3)
Four main mechanisms have been postulated to underlie the
pathogenesis of DN: (1) metabolic processes directly affecting nerve fibres,
(2) endoneurial microvascular disease, (3) autoimmune inflammation, and (4)
deranged neurotrophic support. (2) The metabolic hypothesis states that prolonged
hyperglycaemia leads activation of the polyol pathway through the enzyme aldose
reductase and accumulation of sorbitol and fructose in affected nerves, non-enzymatic
glycosylation of structural nerve proteins and depletion of nerve myoinositol.
These changes lead to abnormal neuronal and axonal metabolism, which in turn,
leads to impaired axonal transport. However, this theory is not fully supported
by pathological studies and clinical trials with aldose reductase inhibitors.
Hyperglycaemia also leads to increased endoneurial vascular resistance and
reduces nerve blood flow.
Microvascular abnormalities lead to
endoneurial hypoxia and subsequent inhibition
of axonal transport and nerve infarction.
Capillary damage leads to further decrease in blood flow
and hypoxia and a vicious cycle is set in motion. Endoneurial hypoxia appears
to be a more important pathogenetic mechanism in type 2 than in type
1 diabetes mellitus. The presence of inflammatory infiltrates in nerves of diabetic
patients supports an autoimmune process. The role of neurotrophic factors is
supported by the observation that
NGF-associated small diameter sensory fibres are
affected before involvement of the other fibre types. (4)
Diabetic neuropathy can be divided into symmetrical and asymmetrical
neuropathies. Symmetrical diabetic neuropathies include distal symmetrical
neuropathy (DSN), diabetic autonomic neuropathy (DAN), small fibre neuropathy
(SFN) and large fibre neuropathy (LFN). Asymmetrical diabetic neuropathies
include single or multiple cranial mononeuropathies (MCM), single or multiple
somatic mononeuropathies (MSM), asymmetrical lumbosacral radiculoplexopathy
(ALR), single or multiple monoradiculopathy (MM) and entrapment neuropathy
(EN). In practice, patients often have multiple subtypes or overlap of these
subtypes. Distal symmetrical neuropathy is the most common form of diabetic
neuropathy. The predominant pathology is axonal degeneration affecting primarily
the sensory nerves. Axonal
degeneration is due dying-back
centripetal degeneration of peripheral axons. (5) In
painful DSN, the principal fibres involved are the
small myelinated and unmyelinated ones, whereas in painless DSN, large myelinated
fibres are predominantly involved. Biopsies of the sural
nerve show loss of myelinated fibres, acute axonal degeneration, some degree
of demyelination and evidence of vasculopathy. Narrowing or closure
of the endoneurial capillary lumen, thickening of
the capillary wall, and marked redundancy of
basement membranes characterize the latter. This type
of neuropathy progresses slowly over months. Demyelination is less prominent
and is probably the result of primary progressive axonal atrophy.
The pathological process for MCM and MSM is
thought to be small vessel occlusive disease. The
precise location of the pathological lesion in ALR
is unknown, but may be in the roots or plexus and
due to occlusion of the vasa nervorum.
Patients with DSN initially complain of numbness and severe
pain in the toes that ascend slowly over months. The hands become affected
when the sensory symptoms reach knee level. Muscle weakness is less prominent,
but difficulty in executing fine finger movements may be noted. Examination
reveals wasting and weakness of the muscles of the hands and feet, diminished
or absent tendon reflexes, glove-and-stocking anaesthesia, foot ulcers and
rarely Charcot joints (particularly the small joints of the feet). Concomitant
autonomic involvement parallels the severity of the neuropathy. Small fibre
neuropathy (SFN) and large fibre neuropathy (LFN) are subtypes of DSN, with
the former presenting with "burning feet" and the latter, a painless
ataxic sensory neuropathy. SFN typically affects the Ad and C fibres.
DAN parallels the severity of DSN, and affects primarily the
cardiovascular, gastrointestinal, genitourinary and integumentary systems.
The spectrum of autonomic involvement varies from subclinical impairment of
cardiovascular reflexes and sudomotor function, to severe cardiovascular, gastrointestinal,
or genitourinary dysfunction. Orthostatic hypotension, resting tachycardia,
a heart rate that does not vary with respiration, loss of sinus arrhythmia,
silent myocardial infarction, symptoms of delayed gastric emptying, paroxysmal
explosive nocturnal diarrhoea, constipation due to colonic atony, urinary retention
with overflow incontinence, impotence, gustatory sweating, distal anhidrosis,
constricted pupils and loss of awareness of hypoglycaemia are recognized features
of DAN.
Orthostatic hypotension is due to failure of the sympathetic
nervous system to increase systemic vascular resistance in the erect posture,
with impairment of compensatory cardiac acceleration. Resting tachycardia is
due to vagal denervation of the heart. Early satiety, nausea, and postprandial
bloating are the principal symptoms of delayed gastric emptying. Bacterial
overgrowth in the gut may occur. Impotence, presenting as both erectile failure
and retrograde ejaculation, occurs in about 30-60% of diabetic men; the majority
of such patients also have some evidence of DSN. Distal anhidrosis causes compensatory
facial and
truncal sweating and heat intolerance.
MCM and MSM most commonly affect the 3rd, 4th,
6th and 7th cranial nerves, and median, ulnar and common
peroneal nerves, respectively. Patients present with acute or subacute onset
of a painful nerve palsy that recovers over weeks or months. The 3rd cranial
nerve palsy in diabetics is painful and typically spares the pupils, reflecting
injury to centrifascicular axons but sparing the peripherally situated papillary
motor fibres of the oculomotor nerve. Rhinocerebral mucormycosis often occurs
in poorly controlled diabetics, and presents with sudden fever, headache, and
malaise, followed by periorbital pain, swelling, and induration. Nasal mucosal
necrosis gives rise to the characteristic black turbinate. Vision loss, total
ophthalmoplegia, and upper hemifacial sensory loss may occur. Left untreated,
occlusion of the internal carotid artery, meningeal extension, obtundation
and death may ensue. Treatment consists of surgical excision of affected tissues
and intravenous amphotericin B. The mortality rate is close to 50% despite
aggressive early treatment. MSM is due to nerve infarction and presents as
acute focal pain, followed by weakness, atrophy and variable sensory loss.
Carpal and cubital tunnel syndromes are the most common presentations
of diabetic EN. As the underlying pathology in EN is primarily focal segmental
demyelination, the recovery is more rapid than MSM.
MM typically affects the T4-T12 roots in older patients with
type 2 diabetes mellitus. Patients complain of truncal pain and dysaesthesias,
described as burning, stabbing, boring, or beltlike pain. Contact with clothing
or bedclothes can be unpleasant. Examination reveals hypaesthesia or hyperpathia
over the thorax or abdomen. The symptoms may persist for several months before
gradually subsiding. The differential diagnoses include intra-abdominal, intrathoracic,
and
intraspinal diseases as well as herpes zoster.
ALR, also known as diabetic amyotrophy, most commonly affects
middle-aged patients with type 2 diabetes mellitus. There is acute or subacute
(over a few days) onset of asymmetric pain and weakness of the proximal lower
limb muscles (iliopsoas, gluteus, thigh adductor, quadriceps, hamstring and
anterior tibial muscles). The progression may be steady or stepwise and may
continue for many months. Weight loss is present in over 50% of patients. Examination
reveals profound atrophy and weakness of the proximal lower limb muscles and
diminished or absent knee and ankle jerks. The nerve conduction study reveals
prolongation of the femoral nerve latencies whilst needle electromyography
shows neurogenic changes (prominent fibrillation potentials) in the affected
muscles (thoracic and lumbar paraspinal muscles). ALR has a poor prognosis
with recovery taking up to 24 months and persistent mild to moderate weakness
is present in many patients. Pain usually recedes spontaneously long before
motor strength begins to improve. Needle EMG reveals, neurogenic motor unit
potential alterations in affected muscles, and prolongation of femoral If suspected,
structural lumbar radiculoplexopathy or cauda equina lesions should be ruled
out with an MRI. Older diabetics may present with a more symmetrical proximal
lower limb paraparesis developing over weeks to months. Overlap with DSN is
noted in up to 60% of patients.
The thoracic nerve roots (notably T4-T12) are the most commonly
affected nerves in MM. Patients present with burning, stabbing, boring or beltlike
chest or abdominal pain. Symptoms may take several months to subside.
An unusual syndrome in adult male type 2 diabetics is diabetic
neuropathic cachexia. In this syndrome, there is massive weight loss (often > 40-50
kg) associated with painful symmetrical polyneuropathy or polyradiculoneuropathy,
depression, insomnia, and impotence. (2)
It is important not to ascribe all unexplained pain, weakness,
or sensory loss in diabetics to diabetic neuropathy. Appropriate investigations
should be directed towards excluding treatable, often dangerous, differential
diagnoses. Superimposed carpal tunnel syndrome, for instance, may mimic worsening
diabetic neuropathy. Compressive lumbar radiculopathy or pelvic malignancy
may masquerade as diabetic lumbosacral radiculoplexopathy. Painful third nerve
palsy may actually be due to a ruptured berry aneurysm in the circle of Willis.
The cornerstone of treatment of diabetic neuropathy is optimization
of glycaemic control. There is good evidence that good diabetic control is
associated with less frequent and less severe peripheral nerve complications.
The Diabetes Control and Complications Trial (1995) showed that intensive glucose
management by insulin pump or by three or more daily insulin injections in
patients with type 1 diabetes mellitus reduces the development of neuropathy
by 64% at 5 years compared with conventional therapy. (6) The benefit from
pancreatic transplantation is short-lived and clinical trials of myoinositol
supplementation have shown conflicting results. Although aldose reductase inhibitors
produce modest changes in nerve conduction and nerve pathology, clinical trials
have failed to produce convincing clinical improvement. In uncontrolled studies,
(7) high-dose intravenous immunoglobulin therapy has been reported to show
benefit in patients with diabetic lumbosacral radiculoplexopathy.
Relief of pain is difficult, but certain drugs may be tried;
these include amitriptyline, carbamazepine, gabapentin, mexiletine and topical
capsaicin. One drug only should be tried at a time. An observation period of
at least 3-4 weeks should be practiced before changing over to another medication.
General measures, such as elevation of the head of the bed (by 15-25cm at night),
increased salt (10-12 d/day) and water intake (>20 oz/day), eating more
frequent small meals rather than a few large meals, and elastic body stockings
may alleviate postural hypotension. Useful drugs include fludrocortisone (0.1-0.6
mg/day), midodrine, (8) phenylpropanolamine (25-50 mg t.d.s.) and ibuprofen
(4oo mg q.i.d.). Gastrointestinal and genitourinary autonomic neuropathy must
be treated symptomatically. Delayed gastric emptying can be treated with Metoclopramide
and nocturnal diarrhoea with short courses of either tetracycline or erythromycin,
or clonidine. Patients with a neurogenic bladder should be encouraged to adhere
to a frequent voiding schedule during the day, which helps reduce the amount
of residual urine. Manual abdominal compression or intermittent self-catheterization
may be needed in more severe cases. Erectile dysfunction may respond to oral
sildenafil, direct vasodilator injection into the copora cavernosa or penile
implants. Both bladder involvement and erectile dysfunction must be treated
in consultation with a urologist.
Daily inspection of the feet, regular pedicure, and prompt
attention to seemingly trivial injuries
and infections are crucial aspects of proper skin
care in diabetics with cutaneous sensory loss,
impaired sweating, and vascular disease. These measures
will minimize the risk of developing foot ulceration
and distal joint destruction (acrodystrophic neuropathy).
Future treatments for diabetic neuropathy should address the
underlying pathogenesis. Supporting evidence from more randomised clinical
trials should be obtained before recommending the routine use of recombinant
human nerve growth factor, antioxidants, NMDA antagonists and essential fatty
acid supplementation. (9-12)
REFERENCES
- Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J
Neurol Neurosurgery Psychiatry 1997; 62: 310-8.
- Bosch EP, Smith BE. Disorders of the Peripheral Nerve.
In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical
Practice Third Edition. Oxford: Butterworth-Heinemann, 2000; 2045-130.
- Thomas PK. Classification, differential diagnosis, and
staging of diabetic neuropathy. Diabetes 1997; 46 Suppl 2:
S54-S57.
- Anand P. Neurotrophins and peripheral neuropathy. Phil
Trans R Soc London 1996; 351: 449-54.
- Dyck PJ, Giannini C. Pathologic alterations in the diabetic
neuropathies of humans: a review. J Neuropathol Exp Neurol 1997; 55:
1181-93.
- Diabetes Control and Complication Trial Research Group.
The effect of intensive diabetes therapy on the development and progression
of neuropathy. Ann Intern Med 1995; 122: 561-8.
- Krendel DA, Costigan DA, Hopkins LC. Successful treatment
of neuropathies in patients with diabetes mellitus. Arch Neurol 1995; 52:
1063-61.
- Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine
vs. placebo in neurogenic orthostatic hypotension. A randomised, double-blind
multicenter study. Midodrine study group. JAMA 1997; 277:
1046-51.
- Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human
nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998; 51:
695-702.
- Ziegler D, Gries FA. Alpha-lipoic acid in the treatment
of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997; 46 Suppl
2: S62-S66.
- Nelson KA, Park KM, Roinovitz E, et al. High-dose oral
dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic
neuralgia. Neurology 1997: 48: 1212-8.
- Horrobin DF. Essential fatty acids in the management of
impaired nerve function in diabetes. Diabetes 1997; 46 Suppl
2: S90-S93.
Copyright 2003 - Malaysian Journal of Medical Sciences
|